Well said. GW Pharma was valued at US$3 billion prior to generating one dollar of revenue from their sole drug, CBD based Epidiolex. And then they were acquired for US$7.4 billion by Jazz Pharma after ramping up revenue.
OSA is a significantly larger market than epilepsy.
If the OSA trials deliver a +10% AHI reduction in a multi, multi billion dollar OSA market then what is that worth to IHL. What’s RMD’s market cap? I know a few people using CPAP and every single person said they’d pop a pill if there was one available because the CPAP machines are terrible (effective but terrible).
And that’s just one indication of 5 that IHL are targeting.
IHL Price at posting:
55.5¢ Sentiment: Buy Disclosure: Held
